# Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer

> **NCT00105950** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 126 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** lapatinib

## Key facts

- **NCT ID:** NCT00105950
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2007-09
- **Final completion:** 2010-05
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2015-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00105950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00105950, "Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT00105950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*